SCYNEXIS (SCYX) has named Sanjay Subramanian as chief financial officer, effective Sept. 9, the company said Thursday.
He succeeds Ivor Macleod, who has retired but will remain at the company through Oct. 9.
Subramanian has more than 20 years of finance and business development experience, most recently as chief financial officer at Inozyme Pharma, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.